Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization

2021 ◽  
Author(s):  
Danny S. C. Ng ◽  
Mary Ho ◽  
Lawrence P.L. Iu ◽  
Timothy Y.Y. Lai
Keyword(s):  
Choroidal Neovascularization ◽  
Safety Review ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf

scholarly journals Macular density alterations in myopic choroidal neovascularization and the effect of anti-VEGF on it

2021 ◽  
Vol 14 (8) ◽  
pp. 1205-1212
Author(s):  
Jian-Bo Mao ◽  
◽  
Jia-Feng Yu ◽  
Xin-Yi Deng ◽  
Chen-Yi Liu ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Capillary Density ◽  
Normal Group ◽  
Reduction Ratio ◽  
Vessel Density ◽  
Lesion Area ◽  
Flow Area ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf ◽  
The Mean

AIM: To analyse macular microvascular alterations in myopic choroidal neovascularization (mCNV) and the efficiency of anti-vascular endothelial growth factor (anti-VEGF) therapy for mCNV by optical coherence tomography angiography (OCTA). METHODS: A total of 123 patients were included in this retrospective study, divided into mCNV group, high myopia (HM) group, and normal group at the Affiliated Eye Hospital of Wenzhou Medical University from January 2017 to January 2019. Superficial vessel density, deep capillary density, foveal avascular zone (FAZ) area, A-circularity index (AI) and vessel density around the 300 μm width of the FAZ region density (FD) and the area of choroidal neovascularization (CNV) lesion (only for mCNV group) were measured on 3×3 mm2 OCTA images. FAZ area was corrected for axial length. Central macular thickness (CMT) was measured on OCT in mCNV group. Compared the parameters on OCTA of 3 groups and pre-anti-VEGF and post-anti-VEGF at 1, 2, 3, and 6mo follow-up in mCNV group. RESULTS: There were significant differences among 3 groups in superficial vessel density, deep capillary density and FD (P<0.05). FAZ area in HM group was smaller than normal group (P<0.05), but there was no significant difference between mCNV group and the other two group. AI increased in mCNV group (P<0.05). The mean CMT, area and flow area of CNV lesion decreased after treatment (P<0.05), while vessel density and FAZ didn’t change. The mean CMT, area and flow area of CNV lesion statistically decreased after anti-VEGF treatment in mCNV group (P<0.05), while superficial vessel density, deep capillary density and FAZ area, AI and FD didn’t change. The mean reduction ratio of lesions was 50.32% (7.07% to 100%). Lesion regression 100% was observed in 2 cases (4.88%). There was a negative correlation between the CNV lesion area and reduction ratio (r=-0.380, P=0.042) and the flow lesion area and reduction ratio (r=-0.402, P=0.030). CONCLUSION: Macular vessel density decreases, FAZ turns smaller and more irregular in mCNV eyes. Anti-VEGF therapy is efficient for mCNV without affecting vessel density and FAZ, but it is unable to completely eliminate CNV lesions in most cases. The bigger mCNV lesions have lower reduction ratio.

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

2014 ◽  
Vol 232 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Paulo Freitas-da-Costa ◽  
João Pinheiro-Costa ◽  
Beatriz Carvalho ◽  
Manuel Falcão ◽  
Elisete Brandão ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Long Term Results ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Drugs ◽  
2016 ◽  
Vol 76 (11) ◽  
pp. 1119-1133 ◽  
Author(s):  
Kelvin Yi Chong Teo ◽  
Wei Yan Ng ◽  
Shu Yen Lee ◽  
Chui Ming Gemmy Cheung
Keyword(s):  
Choroidal Neovascularization ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf

scholarly journals Hyperreflective Material in Optical Coherence Tomography Images of Eyes with Myopic Choroidal Neovascularization May Affect the Visual Outcome

2020 ◽  
Vol 9 (8) ◽  
pp. 2394
Author(s):  
Yasuaki Mushiga ◽  
Sakiko Minami ◽  
Atsuro Uchida ◽  
Norihiro Nagai ◽  
Misa Suzuki ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Choroidal Neovascularization ◽  
Initial Treatment ◽  
Visual Outcome ◽  
Optical Coherence ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf ◽  
The Mean ◽  
Better Than ◽  
Myopic Cnv

The visual outcome of myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor (anti-VEGF) therapy varies among individuals. We retrospectively analyzed the data of 24 eyes (24 patients) with treatment-naïve myopic CNV who underwent anti-VEGF monotherapy following a pro-re-nata regimen at the Division of Medical Retina Clinic, Department of Ophthalmology, Keio University Hospital between May 2014 and December 2017. The mean age was 70.6 ± 2.1 years, and 16 (66.7%) patients were female. Overall, the mean best-corrected visual acuity (BCVA) improved (p = 0.034), and the mean height of the hyperreflective material (HRM), involving the CNV lesion recorded by optical coherence tomography, decreased (p < 0.01) 12 months after the initial treatment. Fifteen eyes (62.5%) achieved a BCVA of better than 0.10 in LogMAR at 12 months; they had a better BCVA (p = 0.015) and lower HRM intensity (p = 0.033) at baseline than the others. Remarkably, the BCVA improved (p < 0.05) and the HRM height (p < 0.01) decreased only in eyes with a final BCVA better than 0.10 as early as 1 month after the initial treatment, which was still present at 12 months. The HRM height and intensity, not only the BCVA, would be valuable in evaluating the prognosis of myopic CNV after anti-VEGF therapy, although further study is required.

Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography for Monitoring Anti-VEGF Therapy in Myopic Choroidal Neovascularization

2014 ◽  
Vol 52 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Pierluigi Iacono ◽  
Maurizio Battaglia Parodi ◽  
Alexandros Papayannis ◽  
Stylianos Kontadakis ◽  
Stefano Da Pozzo ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Fluorescein Angiography ◽  
Choroidal Neovascularization ◽  
Spectral Domain ◽  
Optical Coherence ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf

HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION

Retina ◽  
2018 ◽  
Vol 38 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Pierluigi Iacono ◽  
Maurizio Battaglia Parodi ◽  
Lorenzo Iuliano ◽  
Francesco Bandello
Keyword(s):  
Choroidal Neovascularization ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf ◽  
Vitreomacular Interface

Anti-VEGF-Therapie bei myopischer choroidaler Neovaskularisation: Langzeitergebnisse

2015 ◽  
Vol 1 (1) ◽  
pp. 38-39
Keyword(s):  
Visual Acuity ◽  
Choroidal Neovascularization ◽  
Retinal Thickness ◽  
Central Retinal Thickness ◽  
Myopic Choroidal Neovascularization ◽  
Retrospektive Analyse ◽  
Corrected Visual Acuity ◽  
Anti Vegf ◽  
Best Corrected Visual Acuity

Ziel: Beurteilung der mittel- und langfristigen Wirksamkeit von Anti-VEGF-Wirkstoffen in der Behandlung der choroidalen Neovaskularisation infolge einer pathologischen Myopie (myopic choroidal neovascularization; mCNV).Methoden: Retrospektive Analyse von mCNV-Patienten, die 2 Jahre oder länger mit einer intravitrealen Anti-VEGF-Therapie behandelt worden waren. Wir verglichen die Sehschärfe mit bester Korrektur (best-corrected visual acuity; BCVA) sowie die zentrale Netzhaut-Dicke (central retinal thickness; CRT) vor und nach der Behandlung. Die Anzahl der Injektionen pro Jahr wurde ebenfalls erfasst.Ergebnisse: Auswertungen der Ergebnisse erfolgten nach 2 Jahren für 67 Augen, nach 3 Jahren für 52 Augen, nach 4 Jahren für 28 Augen und nach 5 Jahren für 13 Augen. Die mittlere Veränderung der BCVA gegenüber dem Ausgangswert war nach 2 Jahren signifikant (+8,6 Buchstaben; p < 0,001); diese Verbesserung blieb über einen Zeitraum von 5 Jahren signifikant stabil bestehen. Die mittlere CRT nahm im Verlauf signifikant ab; der Tiefstwert war nach 2 Jahren erreicht (-104,0 μm; p < 0,001). Die mittlere Anzahl der Injektionen betrug im 1. Jahr 5,2 und ging in den nachfolgenden Jahren zurück (p < 0,001).Schlussfolgerung: In der hier beschriebenen Untergruppe von mCNV-Patienten war die intravitreale Anti-VEGF-Therapie über einen Zeitraum von 5 Jahren wirksam, wobei sich der BCVA-Wert fortwährend erhöhte.Übersetzung aus Ophthalmologica 2014;232:57-63 (DOI: 10.1159/000360307)

Sign in / Sign up

Export Citation Format

Share Document